Reference: Law, B. (2020). Priority List of COVID-19 Adverse events of special interest: Quarterly update December 2020. Safety Platform for Emergency Vaccines. Summary: The report updates the list of adverse events of special interest AESI) associated with COVID-19 vaccines, generated by the Safety Platform for Emergency Vaccines (SPEAC) Project. The quarterly review focuses on new […]
Reference: McGee, S., & De Waal, R. (2020). Rapid review of remdesivir for COVID-19: Update 15 December 2020. South African National Department of Health. Summary: The South African National Department of Health conducted a rapid review of remdesivir’s efficacy for treating hospitalised COVID-19 patients. The analysis included five randomised controlled trials (RCTs) with over 7,700
Reference: U.S. Food and Drug Administration. (2020). Vaccines and related biological products advisory committee meeting December 10, 2020 FDA briefing document Pfizer-BioNTech COVID-19 vaccine. https://www.fda.gov/media/144246/download Summary: On December 10, 2020, the Vaccines and Related Biological Products Advisory Committee (VRBPAC) reviewed Pfizer-BioNTech’s COVID-19 vaccine, BNT162b2, which received an Emergency Use Authorization (EUA) request on November 20,